Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

被引：0
|
作者：
X Baraliakos
J Brandt
J Listing
J Sieper
J Braun
机构：
[1] Rheumatology Medical Center Ruhrgebiet,
[2] German Rheumatism Research Center,undefined
[3] University Medicine Berlin,undefined
来源：
Arthritis Research & Therapy | / 7卷
关键词：
Infliximab; Ankylose Spondylitis; Open Label Extension; Infliximab Treatment; Relevant Side Effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Infection and anti-tumor necrosis factor-alpha therapy
    Zandman-Goddard, G
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2003, 5 (11): : 814 - 816
  • [32] Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor α agents
    Braun, J.
    Baraliakos, X.
    Listing, J.
    Davis, J.
    Van der Heijde, D.
    Haibel, H.
    Rudwaleit, M.
    Sieper, J.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (04): : 639 - 647
  • [33] Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare
    Giuseppe Murdaca
    Barbara Maria Colombo
    Gianfranco Barabino
    Matteo Caiti
    Paola Cagnati
    Francesco Puppo
    American Journal of Clinical Dermatology, 2010, 11 : 437 - 439
  • [34] Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database
    Wendling, Daniel
    Joshi, Avani
    Reilly, Patrick
    Jalundhwala, Yash J.
    Mittal, Manish
    Bao, Yanjun
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (12) : 2515 - 2521
  • [35] Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: A case report
    Principi, M
    Di Leo, A
    Ingrosso, M
    Pisani, A
    Marangi, S
    Amoruso, A
    Panella, C
    Francavilla, A
    Ierardi, E
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2004, 26 (02) : 243 - 248
  • [36] Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha
    Tweezer-Zaks, N
    Shiloach, E
    Spivak, A
    Rapoport, M
    Novis, B
    Langevitz, P
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2003, 5 (11): : 829 - 830
  • [37] Nano anti-tumor necrosis factor-alpha based potentiometric sensor for tumor necrosis factor-alpha detection
    Say, Ridan
    Ozkutuk, Ebru Birlik
    Unluer, Ozlem Bicen
    Ugurag, Deniz
    Ersoz, Arzu
    SENSORS AND ACTUATORS B-CHEMICAL, 2015, 209 : 864 - 869
  • [38] Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis
    Norambuena, X.
    Mallol, J.
    Rios, G.
    Quevedo, F.
    Quezada, A.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2007, 35 (02) : 52 - 56
  • [39] Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody infliximab
    Brandt, J
    Haibel, H
    Reddig, J
    Sieper, J
    Braun, J
    JOURNAL OF RHEUMATOLOGY, 2002, 29 (01) : 118 - 122
  • [40] Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha
    Matar, Manar
    Levi, Rachel
    Zvuloni, Maya
    Shamir, Raanan
    Assa, Amit
    PEDIATRIC RESEARCH, 2023, 93 (01) : 131 - 136
12345